RG
KROS icon

Redmile Group’s Keros Therapeutics KROS Stock Holding History

Redmile Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-552,506
Closed -$8.74M – 38
2025
Q3 		$8.74M Hold
552,506
– – 0.85% 24
2025
Q2 		$7.38M Hold
552,506
– – 0.79% 28
2025
Q1 		$5.63M Hold
552,506
– – 0.53% 35
2024
Q4 		$8.75M Hold
552,506
– – 0.61% 35
2024
Q3 		$32.1M Hold
552,506
– – 1.89% 25
2024
Q2 		$25.2M Hold
552,506
– – 1.53% 27
2024
Q1 		$36.6M Buy
+552,506
New +$32.8M 1.34% 29

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Redmile Group's KROS Position: Q4 2025 in Review

Redmile Group sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 552,506 shares — an estimated $8.74M sold.

Redmile Group first reported a position in KROS in Q1 2024 and held it in 7 quarters. The position peaked at $36.6M in Q1 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Redmile Group reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Redmile Group sold 552,506 Keros Therapeutics shares in Q4 2025, an estimated $8.74M.
  • Redmile Group first reported a position in Keros Therapeutics in Q1 2024 and held it in 7 quarters.
  • Redmile Group's Keros Therapeutics position peaked at $36.6M in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Redmile Group's 13F filing for Q4 2025, filed 17 Feb 2026.